Trials / Completed
CompletedNCT02013128
Ublituximab + Ibrutinib in Select B-cell Malignancies
A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ublituximab | Ublituximab (IV infusion) |
| DRUG | Ibrutinib | Ibrutinib oral daily dose |
Timeline
- Start date
- 2014-01-06
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2013-12-17
- Last updated
- 2022-10-24
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02013128. Inclusion in this directory is not an endorsement.